Neoplasms (Cancer / Tumors)NCT06903390
Investigation of the Effect of Information on the Empowerment of Cancer Patients Using Question Prompt List: A Mixed Method Study
A study testing QPL-based Communication Intervention in people with Neoplasms (Cancer / Tumors) and Patient Participation, run by Marmara University at 1 site in Turkey (Türkiye).
Trial summary
Brief Summary The goal of this study is to understand how patient empowerment and a Question Prompt List (QPL) can help cancer patients. The main questions this study aims to answer are: What are the views of nurses, physicians, and cancer patients on patient empowerment? Does using a Question Prompt List (QPL)… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Neoplasms (Cancer / Tumors), Patient Participation, Patient-Centered Care
- What is being tested?
- QPL-based Communication Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 96 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Mar 2024to 1 Mar 2025
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients must be over 18 years old.
- Must understand and speak Turkish.
- Must not have any condition preventing participation (e.g., advanced dementia, cognitive impairment, speech or hearing disorders).
- For healthcare professionals in the qualitative phase: Must have at least one year of experience in oncology.
Who cannot join
- Patients without regular outpatient follow-up visits.
- Patients with severe cognitive or physiological deterioration affecting participation.
- Patients who do not comply with the study process and requirements.
- Patients who voluntarily request to withdraw from the study.
Trial locations and contacts
1 site in 1 country.
About this study
Brief Summary The goal of this study is to understand how patient empowerment and a Question Prompt List (QPL) can help cancer patients.
The main questions this study aims to answer are:
Read more
What are the views of nurses, physicians, and cancer patients on patient empowerment? Does using a Question Prompt List (QPL) improve patient empowerment and reduce anxiety? Researchers will collect qualitative and quantitative data by measuring patient empowerment and anxiety levels.
Who can participate? Cancer patients receiving treatment at Private Anadolu Medical Center Hospital Nurses and physicians working with cancer patients What will participants do? Answer survey questions about their experiences with empowerment, anxiety, and communication Participate in interviews to share their thoughts on patient empowerment Use a Question Prompt List (QPL) during medical consultations Why is this study important? Many cancer patients struggle with anxiety and lack of information about their care.
A Question Prompt List (QPL) may help patients ask better questions, feel more in control of their treatment, and reduce anxiety.
This study will contribute to oncology research and help develop a culture-specific QPL for use in cancer care.
This study will take place at Private Anadolu Medical Center Hospital from January 2023 to November 2024.
- Conditions
- Neoplasms (Cancer / Tumors), Patient Participation, Patient-Centered Care, Health Communication, Patient Empowerment, Anxiety
- Being tested
- QPL-based Communication Intervention
- Medical subject headings
- Neoplasms, Patient Participation, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QPL-based Communication InterventionBehavioural
This QPL-based communication intervention stands out with the following key features:
Patient-Centered \& Cancer-Specific QPL: The intervention uses a QPL tailored for cancer patients, culturally adapted to enhance empowerment and manage anxiety.
Structured Training \& Support: Patients receive training before consultations, with additional guidance for effective QPL use at subsequent visits.
Multiple Assessment Points: The QPL's impact is measured after the first, second, and third consultations, allowing for longitudinal evaluation.
RCT Design: This study is a randomized controlled trial (RCT), comparing the intervention group (QPL) to a control group receiving standard care.
Focus on Empowerment \& Anxiety: Unlike prior studies, this intervention focuses on empowering patients and reducing anxiety, with outcomes measured through validated scales (Patient Empowerment Scale and HADS).
These features differentiate this intervention by offering a structured, culturally relevant approach.
| Study group | Role | What they receive |
|---|---|---|
| "QPL vs. standard care to assess impact on patient empowerment & anxiety in cancer patients. | Experimental | Experimental Group 1 (QPL Communication Intervention Group) Participants in this group will receive a structured communication intervention using the Quick Question List (QPL) during their oncology examinations. The QPL aims to enhance patient empowerment, encourage active participation, and improve communication between patients and healthcare providers. It is designed to help patients express their concerns effectively and engage more actively in their care process.
Intervention:
Implementation of a QPL-based communication strategy in addition to standard oncology care. Receives: Behavioral: QPL-based Communication Intervention |
| Standard Care Group | No intervention | Participants in this group will receive standard physician-patient communication without any additional intervention. This group serves as a control group to evaluate the effectiveness of the QPL-based communication intervention. Intervention: No additional communication tools or interventions will be applied. Patients will receive routine oncology consultations with standard physician-patient interactions. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Patient Empowerment Score
Assessed using the Patient Empowerment Scale to evaluate the effect of QPL-based communication on patient empowerment compared to standard communication. Higher scores indicate greater empowerment.
Measured: Immediately before the first consultation and within 1 day after the second and third consultations
Change in Anxiety Level (HADS)
Measured using the Hospital Anxiety and Depression Scale (HADS) to assess changes in anxiety levels resulting from QPL-based communication versus standard communication. Lower scores indicate lower anxiety.
Measured: Immediately before the first consultation and within 1 day after the second and third consultations
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Mar 2025
- Study start1 Mar 2024
- Primary completion1 Mar 2025
- Study completion1 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neoplasms (Cancer / Tumors)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study is a parallel-group randomized controlled trial designed to assess the impact of QPL-based communication intervention on patient empowerment and anxiety levels in cancer patients. Participants are assigned to either the intervention group (QPL-based communication) or the control group (standard physician-patient communication).
- Masking
- None (open label)
- Enrolment
- 96 participants (actual)
Sponsor and investigators
- Lead sponsor
- Marmara University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Asuman Kuscu, Marmara University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06903390
- Sponsor's protocol ID
- 09.2022.953
- Status last verified
- Mar 2024
- First submitted
- 19 Mar 2025
- Last updated
- 10 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No